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December 20081634 Abstractssecond group, 80 upper extremities were examined with color DU imaging
and digital subtraction angiography; of these, 95% of the brachiocephalic
arteries and 72% of the subclavian arteries were normal. One brachiocephalic
artery had stenosis and one had occlusion, and 15 subclavian arteries were
occluded and another 15 were stenosed. The DU imaging diagnosed 43 of
48 normal sides (90%) correctly, and 14 of 16 cases (88%) of stenosis and 16
of 16 cases (100%) of occlusion were correctly diagnosed. Eight of nine
lesions on the right (89%) and 23 of 24 lesions on the left (96%) were
correctly diagnosed by color DU imaging. Sensitivity, specificity, positive
predictive value, negative predictive value, and accuracy were 88%, 94%,
78%, 97%, and 94%, respectively, for detecting stenosis. There was a high
level of agreement between DU imaging and digital subtraction angiogra-
phy for detecting stenosis ( 0.78) and for detecting occlusion ( 0.96).
Comment: The authors describe excellent results in identifying occlu-
sive lesions of the origin of the subclavian and brachiocephalic arteries. This
was despite the fact that the equipment they used in this study was a bit
dated. A newer machine with smaller footprint probes using the sternal
notch as a window likely would be even more accurate in assessing the great
vessels of the aortic arch. Criteria for stenosis are slightly different than that
used elsewhere. Whereas a peak systolic velocity ratio of 2 indicated
stenosis, stenosis also was also implied by monophasic flow without actual
visualization of a high velocity jet and by reverse flow in a vertebral artery.
These additional criteria are necessary to assess the brachiocephalic vessels. If
only peak systolic velocity ratios are used, the numbers of both false-positive
and false-negative results will be higher.
Functional Assessment at the Buttock Level of the Effect of Aortob-
ifemoral Bypass Surgery
Jaquinandi V, Picquet J, Saumet J-L et al. Ann Surg 2008;247:869-76.
Conclusion: Proximal (hip, buttock, lower back) claudication after
aortobifemoral bypass grafting (AFBG) affects almost one-third of patients
with treadmill walking. Prevalence is higher in patients with end-to-end vs
end-to-side bypass.
Summary: Surprisingly little is known about proximal claudication
after AFBG. In this study, 48 patients performed a treadmill test before and
6 months after AFBG. Exercise-induced proximal claudication and re-
gional pelvic blood flow impairment were studied using the San Diego
Claudication Questionnaire and chest-corrected decrease from rest of trans-
cutaneous oxygen pressure measurements on the buttocks. A decrease from
rest of transcutaneous oxygen pressure values of less than –15 mm Hg was
used to indicate regional blood flow impairment.
Nine women and 39menwere studied. Themean age was 60 9 years.
The lowest ankle-brachial index (ABI) was 0.55  0.18, and maximal
walking distance was 188  192 m at inclusion of the study. After surgery,
ABI and maximal walking distance were improved (0.83 0.19 and 518
359 m respectively, P  .0001). Regional blood flow impairment at the
buttock level was present in 39 patients preoperatively and in 29 patients
after AFBG. Proximal claudication with underlying regional blood flow
impairment in one or both sides was observed in 29 patients before AFBG
and in nine of 26 (41%) vs six of 22 patients (23%) with end-to-end vs
end-to-side proximal aortic graft anastomoses (P  .05).
Comment: It is really not all that surprising that AFBG will not
uniformly improve thigh and buttock claudication, and the patients should
understand this before undergoing the operation. The hypogastric arteries
are generally not revascularized in such cases. The authors’ suggestion that
when technically possible end-to-side rather than end-to-end aortic anasto-
moses should be used to maximum pelvic blood flow does seem reasonable.
Midterm Patency Following Atherectomy for Infrainguinal Occlusive
Disease: A Word of Caution
Chung SW, Sharafuddin MJ, Chigurupati R. Ann Vasc Surgery 2008;22:
358-65.
Conclusions: At 1 year there is poor patency of excisional atherectomy
using the SilverHawk device (FoxHollow Technologies, Redwood City,
Calif).
Summary: The authors sought to evaluate their experience with pe-
ripheral atherectomy using the SilverHawk device. From March 2005
through June 2006, 23 separate atherectomy procedures were done in 19
patients (11 men; age 66  4 years) on 20 limbs. Atherosclerotic lesions
were treated in 18 cases and vein graft stenoses in two. Three redo atherec-
tomies were required for restenotic lesions. Lesions treated were TransAt-
lantic Inter-Society Consensus (TASC) A in three cases, TASC in nine, and
TASCC in eight, with amean number of two treated lesions per limb (range,
1-4). The most distal native stenosis was a superficial femoral artery in 12
cases, the popliteal artery in six, and a tibial artery in two. Eighteen primary
procedures were successful, and all three repeat atherectomy procedures
were successful. Additional balloon dilatation was used in five procedures.
The preoperative ankle-brachial index was 0.51  1.6 and at 1 month
improved to 0.80  0.16 (P  .001). At 12 months, only two vessels
remained patent, with recurrence developing in 16 of the successful primaryprocedures and all three repeat atherectomy procedures. Recurrence was
restenosis in 14 instances and occlusion in five. Major limb amputation was
required in five patients. Primary patency rates per treated limb at 3, 6 and 12
months were 38%, 10%, and 10%, respectively, and the corresponding
assisted primary patency rates were 50%, 23%, and 10%.
Comment: The primary surgeon had previously performed six cases at
another hospital. Most were in conjunction with an industry representative,
and the representative and the surgeon both were satisfied with the imme-
diate technical results of the atherectomy. Therefore, regardless of whether
one is or is not enthusiastic about peripheral atherectomy, the results here
may very well be what an individual surgeon can expect in similar types of
patients with similar lesions. The author’s recommendation that this “time-
consuming modality should be used more judiciously” seems reasonable.
Prevalence and Extent of Dyslipidemia and Recommended Lipid Levels
in US Adults with and without Cardiovascular Comorbidities: the
National Health and Nutrition Examination Surgery 2003-2004
Ghandehari H, Kamal-Bahl S, Wong ND, et al. Am Heart J 2008;156:
112-9.
Conclusion: Adults with cardiovascular disease or related comorbidi-
ties are frequently not at recommended levels for all lipids.
Summary: Data suggest that the extent of treatment and control of
hypercholesterolemia in the United States (US) is poor, with only 35% of
adults in 1999 to 2000 being aware of their hypercholesterolemia, only 12%
on treatment, and 5% controlled (Circulation 2003;107:2185-9). Only
one-fifth of high-risk secondary prevention patients were at goal for low-
density lipoprotein cholesterol (LDL-C) of 100 mg/dL (JAMA 2001;
285:2486-97). The authors of this study evaluated more updated data with
regard to the proportion of adults with cardiovascular disease and related
comorbidities who were at recommended lipid levels. The proportion of US
adults with and without cardiovascular disease or related comorbidities at
(and distant to) recommended levels of LDL-C, non-high-density lipopro-
tein cholesterol (non-HDL-C), HDL-C, and triglycerides. Data were ana-
lyzed from 2883 adults aged 20 years after an 8-hour fast (weighted to a
US population of 128.5 million) from a National Health and Nutrition
Examination Survey 2003-2004, a nationally representative cross-sectional
survey. The number of adults in the National Cholesterol Education Pro-
gram at recommended levels for LDL-C, non-HDL-C, HDL-C, triglycer-
ides, and combined lipids, stratified by ethnicity, age, sex, and the presence
of cardiovascular morbidities was determined.
Of persons without cardiovascular disease or related comorbidities,
85% to 89% were at recommended levels for LDL-C, non-HDL-C,HDL-C,
and triglycerides. However, only 36% to 37% of those with cardiovascular
disease or comorbidities for cardiovascular disease were at recommended
levels for LDL-C and non-HDL-C, and only 17% achieved recommended
levels for all lipids. The treated patients compared with those untreated had
better (ie, lower) LDL-C (112.3 vs 156.7 mg/dL, P  .001) and non-
HDL-C levels (145.9 vs 188.7 mg/dL, P  .001). Levels of HDL-C and
triglycerides were similar in treated and nontreated patients (52.0 vs 50.1
mg/dL, P  .09; and 160.1 vs 148.7 mg/dL, P  .20, respectively).
Comment: The National Cholesterol Education Program promotes
guidelines for goal lipid levels. Treatment recommendations have primarily
focused on management of LDL-C. This emphasis has resulted in improve-
ments in LDL-C levels in the United States. The data here, however, point
out that those patients perhaps in most need of control of their lipid levels
(ie, those with cardiovascular disease or related comorbidities) had really
quite poor overall control of their lipid levels. In patients with cardiovascular
disease, diabetes, or chronic kidney disease, only one-third were at goal
LDL-C and non-HDL-C levels. Only 20% were at recommended levels for
all lipids. That lipid levels are not being achieved in this population may
reflect a lack of awareness, not being treated despite awareness, or inade-
quate treatment. It appears that even greater use of efficacious dosages of
lipid-lowering agents is needed, and likely greater use of combination
therapy, to address patients with multiple lipid disorders, especially if such
patients have cardiovascular disease or significant comorbidities for cardio-
vascular disease.
Thrombolysis with Alteplase 3 to 4.5 Hours After Acute Ischemic
Stroke
HackeW, KasteM, Bluhmki E, and the ECASS Investigators. N Engl J Med
2008;359:1317-29
Conclusion: Intravenous alteplase administered between 3 and 4.5
hours after onset of neurologic symptoms improves clinical outcomes in
patients with acute ischemic stroke.
Summary: The only approved treatment for acute ischemic stroke is
intravenous thrombolysis with alteplase. Approval is for administration 3
hours after onset of symptoms. Efficacy has not been established for admin-
istration after 3 hours following onset of neurologic symptoms in patients
with stroke. In this study the authors tested safety and efficacy of alteplase
when given 3 to 4.5 hours after onset of stroke. Patients underwent a
